A biotechnology company, developing technologies and products to treat cancers and infectious diseases, based on immunological approaches.


Updates from The Motley Fool

Latest updates on Agenus from Fool.com.  The Fool has written over 100 articles on Agenus.
Is Agenus Inc. Stock a Buy?

Agenus' stock has been ripping higher this week, but that doesn't make it a strong buy.

Is Agenus Inc. (AGEN) a Buy?

This cancer-focused biotech will take plenty of shots on goal in the years ahead.

Is Agenus Inc. a Buy?

This small biotech stock is a high-risk but potentially high-reward proposition.

3 Top Biotech Stocks Under $5

Shares of Geron Corporation, Rigel Pharmaceuticals Inc., and Agenus Inc. appear to be trading for...



Stock Performance

View Interactive AGEN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Agenus.
Current Price: $2.98
Prev Close: $2.98
Open: $2.96
Bid: $3.00
Ask: $3.02
Day's Range: $2.88 - $3.07
52wk Range: $1.54 - $6.19
Volume: 2,028,331
Avg Vol 1,836,562
Market Cap: $310M
P/E (ttm): -2.15
EPS (ttm): -$1.39
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Agenus.
CAPS Rating 1 out of 5
 
201 Outperform
92 Underperform
CAPS All Stars
 
24 Outperform
29 Underperform

How do you think Agenus will perform against the market?



You pick for Agenus is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Garo H. Armen, CEO

56% Approve

Based on 2 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Agenus.

A biotechnology company, developing technologies and products to treat cancers and infectious diseases, based on immunological approaches.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers